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Introduction {#sec005}
============

Prediction of prostate cancer (PC) extent and overall pretreatment risk assessment are main challenges in everyday urological practice. In addition to the pathological Gleason Grade Group (GGG) assessed in prostate biopsies (Bx), other variables such as age, prostate-specific antigen (PSA), clinical stage, and biopsy-based tumor volume have been used to predict postoperative tumor characteristics of an individual PC patient \[[@pone.0235779.ref001]--[@pone.0235779.ref005]\]. These variables have also been incorporated into mathematical models to construct tools such as Partin tables, Memorial Sloan Kettering Cancer Center (MSKCC) nomograms and Cancer of the Prostate Risk Assessment (CAPRA) score \[[@pone.0235779.ref002], [@pone.0235779.ref003], [@pone.0235779.ref005]\] in order to improve predictions. Recently, prostate multiparametric magnetic resonance imaging (mpMRI) has been suggested as a tool to improve PC diagnostics and especially of clinically significant PC \[[@pone.0235779.ref004]\]. Prostate Imaging Reporting and Data System (PI-RADS) was introduced in 2012 to standardize the reporting of mpMRI findings \[[@pone.0235779.ref006]\]. The use of the PI-RADS approach is based upon literature evidence and consensus expert opinions \[[@pone.0235779.ref006]\]. However, only a few studies have assessed the value of mpMRI to predict adverse pathology and biochemical recurrence (BCR) in men undergoing RP, and even fewer studies have evaluated the added value of MRI over the pre-existing clinical variables and nomograms, and the results have been conflicting \[[@pone.0235779.ref007]--[@pone.0235779.ref011]\]. Further, combination of mpMRI and predictive nomograms in outcome assessment have not been studied in detail.

The aim of this study was to evaluate the added value of mpMRI in comparison to commonly used clinical variables as well as standard pre- and postoperative nomograms to predict adverse pathology and BCR in men undergoing RP in a contemporary series utilizing PI-RADS reporting system \[[@pone.0235779.ref006], [@pone.0235779.ref012]\].

Materials and methods {#sec006}
=====================

Patient population {#sec007}
------------------

A total of 598 patients underwent robot assisted laparoscopic prostatectomy (RALP) at the HUS Helsinki University Hospital during the study period from January 2014 to September 2015. Of these, 211 (35%) patients underwent RALP without preoperative mpMRI and were excluded from this study. Thus, the study cohort consists of 387 consecutive patients that underwent mpMRI prior to their RALP at treating clinician's discretion. Preoperative clinical and pathological data of the entire cohort were retrieved from the prospective RALP database. These data included age, clinical stage, PSA, primary GS, secondary GS, number of positive biopsies and total number of biopsies. These were markedly the same between the mpMRI cohort and non-mpMRI cohort, confirming that no obvious selection bias existed for patient referral to pre-operative mpMRI ([Table 1](#pone.0235779.t001){ref-type="table"}). At the time of the data curation, we included all the patients having undergone MRI according to contemporary guidelines and having follow-up information in order to conduct survival analysis. Therefore, no formal power calculations were performed but, instead, all patients during the study period were included. The data was accessed and collected between October 2016 and June 2019 from the electronic health records of the HUS Helsinki University Hospital. The original data was accessed based on patients' social security numbers but in the study database all data was handled pseudonymized and according to the study approval by the HUS Helsinki University Hospital. The study was a retrospective registry study and thus no informed consent was required, based on the national and European Union legislation. The study was conducted according to the Declaration of Helsinki and approved by the Institutional Ethics Committee of Helsinki University Hospital (diary number 386/13/03/02/2014).

10.1371/journal.pone.0235779.t001

###### Preoperative variables of all RALP patients with and without preoperative mpMRI.

![](pone.0235779.t001){#pone.0235779.t001g}

                                       Preoperative mpMRI   No preoperative mpMRI         
  ------------------------------------ -------------------- ----------------------- ----- ----------
  **Number of patients**               387                  \-                      211   \-
  **Median age, yrs**                  65                   60--69                  66    61--70
  **Median preoperative PSA, ng/ml**   9.0                  6.2--13.6               8.3   3.6--9.9
  **Biopsy data available**            384                  99.2                    211   100
  **GGG. No.**                                                                            
  **GGG1**                             90                   23.3                    46    21.8
  **GGG2**                             135                  34.9                    83    39.3
  **GGG3**                             105                  27.1                    52    24.6
  **GGG4**                             29                   7.5                     21    10.0
  **GGG5**                             25                   6.5                     9     4.3
  **Median prostate volume, cm^3^**    35                   27--45                  \-    \-
  **Median prostate weight, g**        48                   41--59                  \-    \-

IQR: Interquartile Range, GGG: Gleason Grade Group

mpMRI technique {#sec008}
---------------

Prostate mpMRI was performed without an endorectal coil using a 3.0 T Philips Achieva MRI scanner, which produced 3-mm thick image slices. The modality included T2WI, DWI with ADC mapping and DCE conforming to European Society of Urogenital Radiology guidelines as previously described \[[@pone.0235779.ref006], [@pone.0235779.ref013]\]. The mpMRI data were interpreted by one of the four experienced uroradiologists all of whom were familiar with prostate mpMRI i.e. each uroradiologist had read over 300 prostate mpMRIs per year. At the time, mpMRI data were reported according to PI-RADSv1 recommendations by using a structured formula as follows: number of lesions, tumor volume and maximal diameter, PI-RADS-score, extraprostatic extension (EPE), seminal vesicle invasion (SVI), node status (NS) and radiologic stage.

Prostatectomy specimen and pathologic analysis {#sec009}
----------------------------------------------

RALP was performed transperitoneally and the indication for extended lymphadenectomy was GS ≥4+3 or \>5% risk of lymph node positive disease according to the Memorial Sloan Kettering nomogram \[[@pone.0235779.ref002], [@pone.0235779.ref014]\]. The prostate specimens and lymph nodes were processed as described earlier \[[@pone.0235779.ref015]\]. All prostate material was completely mounted. Lymphadenectomy specimens were mounted per localization. The original pathological diagnosis was made individually by 12 expert pathologists, out of which 4 reported 80% of the cases. Pathological anatomical diagnosis (PAD) report of RALP specimen including primary and secondary GS, tumor volume, margin status, EPE, SVI, NS and pathologic stage (pT) was collected from the RALP database \[[@pone.0235779.ref016]\]. Adverse pathologic findings were defined as EPE, SVI or positive NS.

Statistical analyses {#sec010}
--------------------

Multivariable logistic regression models were used to study the relationship between adverse RP findings (EPE, SVI or positive NS) and clinical variables available before RALP (preoperative PSA, age, cT-stage, percentage of positive biopsy cores, GGG), MSKCC preoperative nomogram and Partin Table estimates. Cox proportional hazards models and Kaplan-Meier survival curves were generated for clinical variables, CAPRA score and MSKCC nomogram parameters in predicting BCR. All models were compiled following the purposeful selection of covariates \[[@pone.0235779.ref017], [@pone.0235779.ref018]\]. Next, available mpMRI variables assessing EPE, SVI or positive NS, prostate volume and PI-RADS score were added to the models. The final models with and without the mpMRI variables were compared by decision curve analysis \[[@pone.0235779.ref019]\], area under the receiver operating characteristics (ROC) curve and multiparametric Wald test. Eighty-one patients had missing values for positive and total biopsy cores and these were imputed using multiple imputation by chained equations \[[@pone.0235779.ref020]\]. An alpha level of 0.05 was used for statistical significance. All statistical analyses were performed with R Statistical Software v.3.6.1 \[[@pone.0235779.ref021]\] using the packages: survival \[[@pone.0235779.ref022]\], precrec \[[@pone.0235779.ref023]\], mfp and mice\[[@pone.0235779.ref020]\].

Results {#sec011}
=======

Cohort {#sec012}
------

Of the 387 mpMRI patients with a median age of 65 years at RALP, preoperative PSA and diagnostic biopsy data were available for 384 patients ([Table 1](#pone.0235779.t001){ref-type="table"}). Distribution of mpMRI, clinical and pathological staging as well as PI-RADS scores and RP GGG are presented in [S1 Table](#pone.0235779.s001){ref-type="supplementary-material"}. The number of patients in each subcohort in the regression models and survival analyses are presented in [S1 Fig](#pone.0235779.s003){ref-type="supplementary-material"}. As Partin tables do not include cT3, patients with clinical T3 were excluded from the analysis concerning Partin tables. Similarly, as CAPRA is designed to predict BCR, it was omitted from the regression models for adverse RP findings.

Predicting adverse findings at RP (Partin, MSKCC, clinical variables, mpMRI) {#sec013}
----------------------------------------------------------------------------

Results of the multivariable logistic regression models for any RP adverse findings are shown in [Table 2](#pone.0235779.t002){ref-type="table"}. Values were dichotomized for clinical stage (\<cT2 versus ≥cT3), GGG (\<2 versus ≥3) and PIRADS score (\<2 versus ≥3). From all considered clinical covariates, age was not significantly associated with any adverse finding. However, based on the known effect to PC risk, age was left in to the model. From mpMRI variables, prostate volume was not significantly associated with any adverse RP finding. All models with mpMRI variables were significantly different from models with clinical variables only based on the multiparametric Wald test (p-values \< 0.001). From the preoperative clinical variables, cT-stage ≥ 3 had the highest odds ratio of 3.98. In addition, The MSKCC nomogram and Partin Table risk predictions were significantly associated with any adverse RP finding (p \< 0.001) with respective odds ratios of 1.05 and 1.03 (1% increase in risk score). In the ROC-AUC analyses, when mpMRI was added to the other models (clinical variables, Partin parameters and MSKCC estimates), all combined models outperformed the individual models without mpMRI. The decision curve analysis showed a net benefit for all models combined with mpMRI for patients with a threshold probability between approximately 10 to 15 and 55 to 75% for any adverse finding ([Fig 1A--1F](#pone.0235779.g001){ref-type="fig"}).

![Additive predictive value of any adverse RP findings by mpMRI in ROC-AUC and Decision curve analysis (DCA) for a-b) clinical characteristics; c-d) Partin table estimates; e-f) MSKCC nomogram parameters.](pone.0235779.g001){#pone.0235779.g001}
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###### Regression model summaries: Prediction of any adverse findings at prostatectomy.

![](pone.0235779.t002){#pone.0235779.t002g}

  Model without mpMRI parameters   Model with mpMRI parameters                                                                                                 
  -------------------------------- ----------------------------- --------------------- ------------- ------------------------- -------- ---------------------- -------------
                                                                                                     **MRI**                                                   
  \-                               \-                            \-                    \-            MRI ANY                   1.420    4.14 (2.641--6.481)    **\<0.001**
  \-                               \-                            \-                    \-            PI-RADS ≥ 3               1.218    3.40 (1.249--9.149)    **0.017**
  \-                               \-                            \-                    \-            MRI prostate volume       -0.013   0.99 (0.972--1.003)    0.095
  **PARTIN**                                                                                         **PARTIN + MRI**                                          
  Partin ANY                       0.026                         1.03 (1.012--1.041)   **\<0.001**   Partin ANY                0.025    1.03 (1.011--1.039)    **\<0.001**
  \-                               \-                            \-                    \-            MRI ANY                   1.277    3.59 (2.116--6.075)    **\<0.001**
  \-                               \-                            \-                    \-            PI-RADS ≥ 3               0.837    2.31 (0.83--6.425)     0.110
  \-                               \-                            \-                    \-            MRI prostate volume       -0.010   0.99 (0.973--1.008)    0.235
  **MSKCC**                                                                                          **MSKCC + MRI**                                           
  MSKCC ANY                        0.053                         1.05 (1.04--1.069)    **\<0.001**   MSKCC ANY                 0.045    1.05 (1.03--1.063)     **\<0.001**
  \-                               \-                            \-                    \-            MRI ANY                   1.139    3.12 (1.944--5.019)    **\<0.001**
  \-                               \-                            \-                    \-            PI-RADS ≥ 3               1.090    2.97 (1.071--8.258)    **0.037**
  \-                               \-                            \-                    \-            MRI prostate volume       -0.017   0.98 (0.968--0.999)    **0.042**
  **CLINICAL**                                                                                       **CLINICAL + MRI**                                        
  PSAPre                           0.041                         1.04 (1.012--1.073)   **0.008**     PSAPre                    0.052    1.05 (1.017--1.091)    **0.003**
  Age                              0.036                         1.04 (0.999--1.076)   0.059         Age                       0.144    1.16 (1.033--1.291)    **0.011**
  GGG ≥ 3                          0.508                         1.67 (1.028--2.686)   **0.039**     GGG ≥ 3                   0.521    1.68 (1.006--2.819)    **0.048**
  Positive Bx(%)                   0.024                         1.02 (1.012--1.036)   **\<0.001**   \% positive biopsies      0.022    1.02 (1.01--1.034)     **\<0.001**
  cT ≥ 3                           1.382                         3.98 (2.029--7.817)   **\<0.001**   cT ≥ 3 given MRI ANY      2.047    7.74 (1.868--32.093)   **0.005**
  \-                               \-                            \-                    \-            cT ≥ 3 given MRI OC       0.426    1.53 (0.659--3.56)     0.323
  \-                               \-                            \-                    \-            MRI ANY given cT ≥ 3      1.218    3.38 (1.939--5.893)    **\<0.001**
  \-                               \-                            \-                    \-            MRI ANY given cT \< 3     -0.403   0.67 (0.14--3.187)     0.614
  \-                               \-                            \-                    \-            PI-RADS ≥ 3               1.104    3.02 (0.985--9.236)    0.054
  \-                               \-                            \-                    \-            MRI prostate volume       0.184    1.20 (1.002--1.442)    **0.049**
  \-                               \-                            \-                    \-            Age x MRI prostate vol.   -0.003                          **0.033**
  \-                               \-                            \-                    \-            cT ≥ 3 x MRI ANY          -1.621                          0.056

MRI: magnetic resonance imaging; ANY: suggestion of extraprostatic extension, seminal vesicle invasion or lymph node involvement; OC: organ-confined (≤pT2); cT: clinical stage

BCR free survival (CAPRA, MSKCC, clinical variables, mpMRI) {#sec014}
-----------------------------------------------------------

Kaplan-Meier survival plots revealed that all preoperative clinical variables and mpMRI indicating adverse RP findings separate the patient cohort into two groups with different survival probability (for all variables p\< 0.01 in log rank test, [S2A--S2F Fig](#pone.0235779.s004){ref-type="supplementary-material"}). Neither mpMRI prostate volume (\> 35 cc) nor the PIRADS score higher than two separated the groups significantly ([S3A and S3B Fig](#pone.0235779.s005){ref-type="supplementary-material"}).

In the Kaplan-Meier analysis, CAPRA risk score separated the patients into three distinct groups ([Fig 2A--2C](#pone.0235779.g002){ref-type="fig"}). In the CAPRA dataset, the time for BCR was significantly shorter when the mpMRI indicates adverse RP findings, than for the patients with favorable mpMRI findings. Additionally, for the high risk CAPRA group, mpMRI adverse findings separates the patients into two groups with significantly different survival times. In the intermediate CAPRA risk group, there were no differences in the survival times based on mpMRI findings ([S4 Fig](#pone.0235779.s006){ref-type="supplementary-material"}). For the low risk groups, there were only two events, thus no comparisons could be made.

![BCR free survival probability--a) Kaplan-Meier survival analysis for CAPRA risk groups; b) Survival plots for mpMRI any adverse finding (ANY) versus organ confined (OC) in the CAPRA group; c) Survival plot for mpMRI any adverse finding (ANY) versus organ confined (OC) in the CAPRA high risk group.](pone.0235779.g002){#pone.0235779.g002}

When we looked at the MSKCC 3-year survival probability, a cut-off value of 80% significantly separated the patients into two groups with different survival probabilities ([Fig 3A](#pone.0235779.g003){ref-type="fig"}). In the high risk group, the mpMRI for any adverse RP finding significantly added value, separating the group into two cohorts with significantly different survival curves ([Fig 3B](#pone.0235779.g003){ref-type="fig"}). In the low risk MSKCC group there were no differences in the survival times based on mpMRI findings ([S5 Fig](#pone.0235779.s007){ref-type="supplementary-material"}).

![BCR free survival probability--a) Kaplan-Meier survival analysis for MSKCC BCR free survival at 80% after 3 years; b) Survival plot for mpMRI any adverse finding (ANY) versus organ confined (OC) in the MSKCC BCR high risk group (\<80%).](pone.0235779.g003){#pone.0235779.g003}

As a positive surgical margin is a strong predictor of BCR all survival analyses were also done by excluding patients with a positive surgical margin \[[@pone.0235779.ref024]\]. All described results remained significant except for patient age (\> 65 years), where the p-value increased to 0.633.

The cox proportional hazard models showed that mpMRI features associating with adverse RP findings correlate with BCR in an univariate model ([S2 Table](#pone.0235779.s002){ref-type="supplementary-material"}). However, when comparing models with and without the mpMRI indicating for adverse RP findings, no significant differences between the models were observed in the multivariable Wald test.

Discussion {#sec015}
==========

Here, we have addressed the value of combining mpMRI with clinical parameters, MSKCC nomogram and Partin nomogram to predict EPE, SVI or NS as adverse findings in RP in a contemporary cohort of PC patients. We can conclude that mpMRI improves the prediction of adverse pathology at RP when added to traditional preoperative prediction tools over a wide range of decision thresholds. Furthermore, mpMRI significantly added to the prediction of BCR when combined with the commonly used predictive tools CAPRA and MSKCC nomograms.

Our results on mpMRI-based prediction of adverse pathology at RALP are mostly in concordance with the literature. In a meta-analysis by de Rooij et al., a total of 75 studies (9796 patients) were analyzed and pooled for EPE (45 studies, 5681 patients), SVI (34 studies, 5677 patients), and overall stage T3 detection (38 studies, 4001 patients). The analysis for MRI found sensitivities and specificities for EPE, SVI and overall stage T3 detection of 0.57 and 0.91; 0.58 and 0.96; and 0.61 and 0.88, respectively. Functional imaging in addition to T2-weighted imaging and use of higher field strengths (3T) improved sensitivity for EPE and SVI. However, the heterogeneity of the studies included in the meta-analysis and the variability of the reported techniques (including pre PI-RADS era studies) hamper the interpretation of the results \[[@pone.0235779.ref025]\].

Recently, Morlacco et al. similarly evaluated the incremental value of MRI in a pre PI-RADS era (2003 to 2013) prostatectomy cohort \[[@pone.0235779.ref007]\]. The authors evaluated 914 patients with preoperative MRI of which 501 patients with endorectal coil MRI were eventually included in their analysis. They conclude that MRI provides added staging value and they also speculate that the inherent limitations in their study (pre PI-RADS era and high-risk patient cohort) may actually underestimate the added value of MRI. Our results suggest added value for MRI as a staging tool in the PI-RADS era. The study cohorts are relatively similar in respect to the risk factors (e.g. ≥pT3 49% vs 44%) but they substantially differ in MRI technique used (1.5T MRI and endorectal coil versus 3T pelvic coil and non-structured vs structured reporting). Furthermore, it is not possible to analyze the extent of selection bias in the Morlacco study as they did not report the characteristics of the cohort that did not undergo MRI \[[@pone.0235779.ref007]\]. Thus, one may speculate that clinical decision making was skewed towards guiding patients to MRI that were more likely to benefit from it. In addition to the AUC analysis, our decision curve analysis data suggested that the added net benefit for MRI extends over a wide range of threshold probabilities for EPE and SVI. Interestingly, another cohort with endorectal coil and no PI-RADS reported added value of preoperative MRI for staging of SVI \[[@pone.0235779.ref012]\]. The authors of that study reported significantly higher AUC values for Partin residues to predict SVI with and without MRI of 0.84 and 0.93, respectively, when compared to our data (0.68 and 0.73, respectively), suggesting different background risk in the two cohorts.

Gupta et al \[[@pone.0235779.ref026]\] addressed the accuracy of mpMRI and Partin Tables to predict EPE, but did not analyze the added value of mpMRI. In their analysis of only 60 patients, the ability of Partin Tables to predict EPE was comparable to ours (AUC of 0.62 vs 0.56). The mpMRI in their analysis, on the other hand, was a clearly better predictor of EPE than in our analysis (AUC of 0.82 vs 0.62). Significantly better predictive improvements have also been reported for MRI, when added to the Partin clinical model. In a subsequent study in 2016 Gupta et al found no added benefit of substituting multiparametric MRI stage for clinical stage (AUC of 0.63) to define organ-confined (OC) disease when using Partin tables (AUC of 0.70), while mpMRI was valuable as a stand-alone staging test (AUC 0.88) \[[@pone.0235779.ref027]\]. AUCs reported by Feng et al. for Partin and MSKCC nomograms predicting EPE were 0.85 and 0.86 and increased to 0.92 and 0.94, respectively, when mpMRI was added to each nomogram \[[@pone.0235779.ref028]\]. The Feng et al. and Gupta et al. studies relied on only one radiologist in their respective protocols to report the MRI results, which diminishes the effect of interreader variability in the results of both studies \[[@pone.0235779.ref026]--[@pone.0235779.ref028]\].

Our data suggests that when added to well-known prediction tools, prostate mpMRI aids in predicting BCR after RP, as it supports a more specific classification within the high risk CAPRA and MSKCC groups. Even as a standalone investigation, mpMRI was able to separate two groups with distinct BCR survival. Our results are in concordance with a small pre-PI-RADS era study where the ability of mpMRI to predict BCR after RP was seen, while the added value to CAPRA or MSKCC was not assessed \[[@pone.0235779.ref029]\]. As mpMRI is in part a surrogate method to predict RP findings, standardization of mpMRI reporting is expected to further improve its predictive value, as it is well known that adverse RP findings can predict BCR.

PI-RADS version 1 was the recommended reporting platform at the time of our study. PI-RADS version 2 or 2.1 may improve the inter-observer variability and diagnostic reliability \[[@pone.0235779.ref030]\]. Instead of a more recent PIRADS 2/2.1 cohort, we chose to analyze a PIRADS 1 cohort with longer follow-up time, which allowed us to use BCR as a study end point. The experience of the four radiologists in our study may be advantageous in diminishing inter-observer variability, especially for tumors in the peripheral zone as these are less dependent on the PI-RADS \[[@pone.0235779.ref031]\].

Taken together, the evidence in the current literature tend to support the use of preoperative MRI as a staging tool, especially in regard to EPE and SVI. Despite the uncertainty of exactly predicting the presence of EPE or SVI, all the information combined, i.e. the size and location of the tumor among many other MRI and clinical variables may influence preoperative decision making and planning of the surgical procedure. This was recently shown in a retrospective cohort in which patients that had preoperative MRI were more likely to undergo non-nervesparing RP and had lower likelihood of positive surgical margins \[[@pone.0235779.ref024]\].

While the literature and the results by us may support the role of MRI as a staging tool for EPE and SVI preoperatively, the case is less clear for nodal status where a pooled sensitivity of only 0.39 has been reported \[[@pone.0235779.ref032]\]. A significant proportion of lymph node metastases are microscopic and enlarged lymph nodes may be reactive thereby hampering the size criterion in nodal status evaluation with any imaging modality, including MRI. Contrary to our results, recently a nomogram incorporating MRI has been developed to predict nodal status before RP \[[@pone.0235779.ref033]\]. This nomogram does not rely on the evaluation of the nodal status *per se* by MRI (contrary to our analysis). Instead, several MRI related variables are added to the existing model. This further supports the use of MRI preoperatively despite the actual evaluation of nodal status seems to be suboptimal with the current MRI techniques.

The limitations of our study include retrospective analysis of single center data. Selection bias cannot be ruled out as not all patients had preoperative MRI during the study period. However, no obvious differences where noted when we compared the demographics of these groups. Furthermore, in order to enhance diagnostic accuracy, to improve translational PC research and to better integrate MRI with pathology and to support clinical decision making, pathologists are encouraged to adopt regional reporting system similar to the PI-RADS \[[@pone.0235779.ref034]\].

Preoperative prostate MRI adds to prediction of adverse findings at RP and BCR after RP. As mpMRI is more commonly used for risk stratification at prebiopsy setting, mpMRI parameters are becoming more readily available and should be considered as additional source of information to the standard predictive nomograms.
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\"JE Orion Research Foundation sr

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

7\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

8\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a nice retrospective study that among other studies is trying to establish what role mpMRI has in pre-treatment evaluation in men with prostate cancer. While there are many studies on this subject, many of which are referred to in the manuscript, I do think that having the experience of multiple centeres during this growing phase of mpMRI in prostate cancer evaluation is necessary to inform future necessary randomized controlled trials.

Specific questions I have:

\- I understand that perhaps this was not a question the authors were addressing in this manuscript, and perhaps could be reserved for another study, but why did they not include positive surgical margin in their analysis? I would say many surgeons try to rely on preoperative MRI to guide their resection, and PSM would be an \"adverse pathologic feature.\" Again, if the authors intent was simply to see the effect on established preoperative nomograms then I understand the exlusion, but I do feel it would be a simple addition to the paper and very helpful

\- The authors do not explicitly state what their defintion of \"adverse pathologic features\" was. EPE, SVI, and node positive disease are inferred, but this is not explicity stated and I think needs to be clarified.

-While all MRIs were read my 4 qualified radiologists, can the authors clarify if the pathology readings were centralized by a single or small group of pathologists?

\- I do not know if it is the formatting of the pdf file, but the tables are listed in the middle of the manuscript while the figures (without description) are listed at the end. This did make the manuscript difficult to follow.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Keith J. Kowalczyk

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

10 Jun 2020

Rebuttal letter

PONE-D-20-03900

1\. Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We have reviewed and corrected the manuscript to match the PLOS ONE style requirements.

\*\*\*\*\*\*\*\*\*\*

2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients\' medical records were accessed; and c) the source of the medical records analyzed in this work (e.g. hospital, institution or medical center name). If patients provided informed written consent to have data from their medical records used in research, please include this information.

Response: The suggested changes have been made to the manuscript.

Revised manuscript (Materials and methods: Patient population. Sentences added): The data was accessed and collected between October 2016 and June 2019 from the electronic health records of the HUS Helsinki University Hospital. The original data was accessed based on patients' social security numbers but in the study database all data was handled pseudonymized and according to the study approval by the HUS Helsinki University Hospital. The study was a retrospective registry study and thus no informed consent was required, based on the national and European Union legislation. The study was conducted according to the Declaration of Helsinki and approved by the Helsinki University Hospital ethics committee (diary number 386/13/03/02/2014).

\*\*\*\*\*\*\*\*\*\*

3\. Please confirm in your methods section and ethics statement that the diary number stated in the ethics statement refers to the approval number issued by the ethics committee.

Response: The diary number has been checked and assured to refer to the approval number.

\*\*\*\*\*\*\*\*\*\*

4\. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

Response: Study sample size is addressed in the chapter Materials and methods: Patient population. The study included retrospective data on 387 consecutive radical prostatectomy patients that were diagnosed according to the contemporary multiparametric MRI and had a reasonably long follow-up time. Therefore, no formal power calculations were performed but, instead, all patients during the study period were included.

Revised manuscript (Materials and methods: Patient population. Sentences added): At the time of the data curation, we included all the patients having undergone MRI according to contemporary guidelines and having follow-up information in order to conduct survival analysis. Therefore, no formal power calculations were performed but, instead, all patients during the study period were included.

\*\*\*\*\*\*\*\*\*\*

5\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

Response: The ORCID ID of the corresponding author has been updated.

\*\*\*\*\*\*\*\*\*\*

6\. Thank you for stating the following in the Acknowledgments Section of your manuscript: \"This study has been funded by Cancer Society Finland (TM, AR), Academy of Finland (TM), and HUS Helsinki University Hospital (TM, AR).\" We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"JE Orion Research Foundation sr The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

Response: We have removed the funding information from the Acknowledgments section and updated the Funding Statement in the online submission form.

\*\*\*\*\*\*\*\*\*\*

7\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response: The suggested changes have been made to the manuscript and we have added the data previously not shown as supplementary files.

Revised manuscript (Results: BCR free survival (CAPRA, MSKCC, clinical variables, mpMRI). Sentence corrected):

Neither mpMRI prostate volume (\> 35 cc) nor the PIRADS score higher than two separated the groups significantly (Fig S3 a-b).

Previous manuscript:

Neither mpMRI prostate volume (\> 35 cc) nor the PIRADS score higher than two separated the groups significantly (data not shown).

Revised manuscript (Results: BCR free survival (CAPRA, MSKCC, clinical variables, mpMRI):

In the intermediate CAPRA risk group, there were no differences in the survival times based on mpMRI findings (Fig S 4). For the low risk groups, there were only two events, thus no comparisons could be made.

Previous manuscript:

In the low and intermediate CAPRA risk groups, there were no differences in the survival times based on mpMRI findings (data not shown).

Revised manuscript (Results: BCR free survival (CAPRA, MSKCC, clinical variables, mpMRI). Sentence corrected):

In the low risk MSKCC group there were no differences in the survival times based on mpMRI findings (Fig S 5).

Previous manuscript:

In the low risk MSKCC group there were no differences in the survival times based on mpMRI findings (data not shown).

\*\*\*\*\*\*\*\*\*\*

8\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response: Suggested corrections were made according to the Supporting Information guidelines.

Revised manuscript (Supporting information added):

Supporting information

S1 Table. Supplementary table 1 a) Comparison of mpMRI, clinical and pathological staging. Distribution of lymph node finding; 1 b) Distribution of PI-RADS and prostatectomy grading. PI-RADS score in multiparametric MRI and Gleason Grade Group for ROI1.

S2 Table. Supplementary table 2. Cox proportional hazard model summaries: prediction of biochemical recurrence.

S1 Fig. Flowchart for the analyses. LND: Lymph node dissection. CAPRA = Cancer of the Prostate Risk Assessment; MRI = magnetic resonance imaging.

S2 Fig. BCR free survival probability -- Kaplan-Meier survival analysis for clinical parameters: a) clinical T-stage equal or higher than 3 (follow-up data for clinical T-stage missing for one patient); b) Gleason Grade Group equal or higher than 3; c) preoperative PSA equal or higher than 10 µg/l; d) percentage of positive biopsies equal or higher than 50%; e) MRI prediction for any adverse finding; f) age at operation equal or higher than 65 years .

S3 Fig. BCR free survival probability -- Kaplan-Meier survival analysis for clinical parameters: a) mpMRI prostate volume (\> 35 cc); b) PIRADS score higher than two.

S4 Fig. BCR free survival probability -- Kaplan-Meier survival analysis for low risk MSKCC group.

S5 Fig. BCR free survival probability -- Kaplan-Meier survival analysis for low risk MSKCC group.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

2\. Reviewers' Comments to the Author

1\. I understand that perhaps this was not a question the authors were addressing in this manuscript, and perhaps could be reserved for another study, but why did they not include positive surgical margin in their analysis? I would say many surgeons try to rely on preoperative MRI to guide their resection, and PSM would be an \"adverse pathologic feature.\" Again, if the authors intent was simply to see the effect on established preoperative nomograms then I understand the exlusion, but I do feel it would be a simple addition to the paper and very helpful

Response: We thank the reviewer for this valuable comment. As stated, the PSM is not a part of the preoperative nomograms in this study. PSM is very much surgeon and hospital dependent and other adverse pathology findings in RP (i.e. EPE, SVI and LN) have been also shown to have impact on survival. However, the role and impact of preoperative MRI on surgical strategy (nerve sparing vs no nerve sparing), surgical margin status, and postoperative function are the scope of another separate ongoing analysis.

No corrections in the manuscript were made.

\*\*\*\*\*\*\*\*\*\*

2\. The authors do not explicitly state what their defintion of \"adverse pathologic features\" was. EPE, SVI, and node positive disease are inferred, but this is not explicity stated and I think needs to be clarified.

Response: We have now clarified the definition of adverse pathologic features better in the manuscript.

Revised manuscript (Materials and methods. Prostatectomy specimen and pathologic analysis. Sentence added): Adverse pathologic findings were defined as EPE, SVI or positive NS.

\*\*\*\*\*\*\*\*\*\*

3\. While all MRIs were read my 4 qualified radiologists, can the authors clarify if the pathology readings were centralized by a single or small group of pathologists?

Response: We had altogether 12 pathologists performing the pathology readings, and five of them performed over 80% of the readings. We have now better clarified this in the manuscript.

Revised manuscript (Materials and methods. Prostatectomy specimen and pathologic analysis. Sentence added): The original pathological diagnosis was made individually by 12 expert pathologists, out of which 4 reported 80% of the cases.

\*\*\*\*\*\*\*\*\*\*

4\. I do not know if it is the formatting of the pdf file, but the tables are listed in the middle of the manuscript while the figures (without description) are listed at the end. This did make the manuscript difficult to follow.

Response: The manuscript has now been carefully reviewed and corrected to match the PLOS ONE style requirements.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
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Dear Dr. Sandeman,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Isaac Yi Kim, MD, PhD

Academic Editor
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Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy

Dear Dr. Sandeman:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Isaac Yi Kim

Academic Editor
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